MX2020001223A - Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. - Google Patents
Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.Info
- Publication number
- MX2020001223A MX2020001223A MX2020001223A MX2020001223A MX2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A MX 2020001223 A MX2020001223 A MX 2020001223A
- Authority
- MX
- Mexico
- Prior art keywords
- tatk
- compositions
- formulations
- cdkl5 fusion
- fusion proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002299 complementary DNA Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere composiciones y formulaciones que contienen una proteína de fusión TATk-CDKL5. También se describen métodos para producir una proteína de fusión TATk-CDKL5 a partir de vectores que contienen ADNc de TATk-CDKL5 y métodos para transducir células con los vectores que contienen ADNc de TATk-CDKL5 y la proteína de fusión TATk-CDKL5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946280P | 2014-02-28 | 2014-02-28 | |
| PCT/IB2015/000999 WO2015128746A2 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020001223A true MX2020001223A (es) | 2022-05-31 |
| MX392778B MX392778B (es) | 2025-03-24 |
Family
ID=53539745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001223A MX392778B (es) | 2014-02-28 | 2015-02-27 | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas |
| MX2016011167A MX2016011167A (es) | 2014-02-28 | 2015-02-27 | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011167A MX2016011167A (es) | 2014-02-28 | 2015-02-27 | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9290746B2 (es) |
| EP (2) | EP3110837B1 (es) |
| JP (2) | JP6629747B2 (es) |
| KR (1) | KR102307276B1 (es) |
| CN (1) | CN106255706A (es) |
| AU (2) | AU2015221860B2 (es) |
| BR (1) | BR112016019868B1 (es) |
| CA (1) | CA2940401C (es) |
| CL (1) | CL2016002142A1 (es) |
| CR (1) | CR20160392A (es) |
| CY (2) | CY1122644T1 (es) |
| DK (2) | DK3110837T3 (es) |
| DO (1) | DOP2016000220A (es) |
| EA (2) | EA038000B1 (es) |
| ES (2) | ES2745335T3 (es) |
| HR (2) | HRP20191511T1 (es) |
| HU (2) | HUE045393T2 (es) |
| IL (2) | IL247481B (es) |
| LT (2) | LT3110837T (es) |
| MX (2) | MX392778B (es) |
| MY (1) | MY181566A (es) |
| NI (1) | NI201600127A (es) |
| PE (1) | PE20161406A1 (es) |
| PH (1) | PH12016501689B1 (es) |
| PL (2) | PL3110837T3 (es) |
| PT (2) | PT3608334T (es) |
| RS (2) | RS62244B1 (es) |
| SG (2) | SG10202000537RA (es) |
| SI (2) | SI3608334T1 (es) |
| SM (2) | SMT202100478T1 (es) |
| SV (1) | SV2016005264A (es) |
| WO (1) | WO2015128746A2 (es) |
| ZA (2) | ZA201606655B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045393T2 (hu) * | 2014-02-28 | 2019-12-30 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, kiszerelések és alkalmazásuk |
| CA3029473A1 (en) * | 2016-06-28 | 2018-01-04 | Alma Mater Studiorum - Universita Di Bologna | Tat.kappa.-cdkl5 fusion proteins, compositions, formulations, and use thereof |
| CN111936624A (zh) * | 2017-11-30 | 2020-11-13 | 阿米库斯治疗学公司 | Cdkl5表达变体和cdkl5融合蛋白 |
| US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
| JP2022554267A (ja) * | 2019-10-30 | 2022-12-28 | アミカス セラピューティックス インコーポレイテッド | 組換えｃｄｋｌ５タンパク質、遺伝子療法、及び製造方法 |
| IT202000025423A1 (it) * | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| AU2021392642A1 (en) | 2020-12-01 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG189519A1 (en) * | 2010-10-25 | 2013-05-31 | Univ D Axi Marseille | TREATMENT OF MeCP2-ASSOCIATED DISORDERS |
| HUE045393T2 (hu) * | 2014-02-28 | 2019-12-30 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, kiszerelések és alkalmazásuk |
-
2015
- 2015-02-27 HU HUE15736034A patent/HUE045393T2/hu unknown
- 2015-02-27 ES ES15736034T patent/ES2745335T3/es active Active
- 2015-02-27 RS RS20211041A patent/RS62244B1/sr unknown
- 2015-02-27 CA CA2940401A patent/CA2940401C/en active Active
- 2015-02-27 MX MX2020001223A patent/MX392778B/es unknown
- 2015-02-27 KR KR1020167026521A patent/KR102307276B1/ko active Active
- 2015-02-27 HU HUE19179287A patent/HUE055282T2/hu unknown
- 2015-02-27 PL PL15736034T patent/PL3110837T3/pl unknown
- 2015-02-27 SI SI201531680T patent/SI3608334T1/sl unknown
- 2015-02-27 HR HRP20191511 patent/HRP20191511T1/hr unknown
- 2015-02-27 PE PE2016001528A patent/PE20161406A1/es not_active Application Discontinuation
- 2015-02-27 SI SI201530884T patent/SI3110837T1/sl unknown
- 2015-02-27 CR CR20160392A patent/CR20160392A/es unknown
- 2015-02-27 CN CN201580010858.9A patent/CN106255706A/zh active Pending
- 2015-02-27 SM SM20210478T patent/SMT202100478T1/it unknown
- 2015-02-27 EA EA201691691A patent/EA038000B1/ru unknown
- 2015-02-27 EA EA202190727A patent/EA202190727A3/ru unknown
- 2015-02-27 DK DK15736034.8T patent/DK3110837T3/da active
- 2015-02-27 EP EP15736034.8A patent/EP3110837B1/en active Active
- 2015-02-27 WO PCT/IB2015/000999 patent/WO2015128746A2/en not_active Ceased
- 2015-02-27 LT LTEP15736034.8T patent/LT3110837T/lt unknown
- 2015-02-27 SG SG10202000537RA patent/SG10202000537RA/en unknown
- 2015-02-27 PT PT191792878T patent/PT3608334T/pt unknown
- 2015-02-27 RS RSP20191144 patent/RS59344B1/sr unknown
- 2015-02-27 MY MYPI2016001567A patent/MY181566A/en unknown
- 2015-02-27 SM SM20190504T patent/SMT201900504T1/it unknown
- 2015-02-27 US US14/633,757 patent/US9290746B2/en active Active
- 2015-02-27 AU AU2015221860A patent/AU2015221860B2/en active Active
- 2015-02-27 LT LTEP19179287.8T patent/LT3608334T/lt unknown
- 2015-02-27 PL PL19179287T patent/PL3608334T3/pl unknown
- 2015-02-27 JP JP2016553630A patent/JP6629747B2/ja active Active
- 2015-02-27 ES ES19179287T patent/ES2885245T3/es active Active
- 2015-02-27 PT PT15736034T patent/PT3110837T/pt unknown
- 2015-02-27 MX MX2016011167A patent/MX2016011167A/es active IP Right Grant
- 2015-02-27 DK DK19179287.8T patent/DK3608334T3/da active
- 2015-02-27 SG SG11201606863YA patent/SG11201606863YA/en unknown
- 2015-02-27 EP EP19179287.8A patent/EP3608334B1/en active Active
- 2015-02-27 BR BR112016019868-9A patent/BR112016019868B1/pt not_active IP Right Cessation
-
2016
- 2016-03-21 US US15/075,457 patent/US9944910B2/en active Active
- 2016-08-23 DO DO2016000220A patent/DOP2016000220A/es unknown
- 2016-08-24 CL CL2016002142A patent/CL2016002142A1/es unknown
- 2016-08-25 PH PH12016501689A patent/PH12016501689B1/en unknown
- 2016-08-25 IL IL247481A patent/IL247481B/en active IP Right Grant
- 2016-08-26 NI NI201600127A patent/NI201600127A/es unknown
- 2016-08-26 SV SV2016005264A patent/SV2016005264A/es unknown
- 2016-09-26 ZA ZA2016/06655A patent/ZA201606655B/en unknown
-
2018
- 2018-04-16 US US15/954,021 patent/US10584318B2/en active Active
-
2019
- 2019-08-20 AU AU2019219743A patent/AU2019219743B2/en active Active
- 2019-09-11 CY CY20191100949T patent/CY1122644T1/el unknown
- 2019-09-25 ZA ZA2019/06304A patent/ZA201906304B/en unknown
- 2019-12-05 JP JP2019220178A patent/JP6896050B2/ja active Active
-
2020
- 2020-03-06 US US16/811,484 patent/US10907138B2/en active Active
- 2020-06-17 IL IL275435A patent/IL275435B/en unknown
-
2021
- 2021-08-17 HR HRP20211324TT patent/HRP20211324T1/hr unknown
- 2021-08-19 CY CY20211100743T patent/CY1124727T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312989A (en) | Il15/il15rα heterodimeric fc-fusion proteins | |
| MX2020001223A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. | |
| MX2023011785A (es) | Metodos y composiciones para produccion de proteina de clara de huevo. | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| MX2023001834A (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| MX382518B (es) | Antigenos de citomegalovirus y su uso. | |
| BR112016030965A2 (pt) | Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| TWD170353S (zh) | 項鍊 | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| MX421186B (es) | Constructos de anticuerpos. | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX377774B (es) | Formulaciones de proteinas. | |
| EP4467565A3 (en) | Anti-tnf alpha antibody formulations | |
| EP3888671A3 (en) | Protein formulations |